Hippo MST1/2 LATS1/2
Selected indexed studies
- The Hippo Pathway: Biology and Pathophysiology. (Annu Rev Biochem, 2019) [PMID:30566373]
- WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy. (Mol Cell, 2022) [PMID:35429439]
- Low MST1/2 and negative LATS1/2 expressions are associated with poor prognosis of colorectal cancers. (Pathol Res Pract, 2023) [PMID:37302275]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- The Hippo Pathway: Biology and Pathophysiology. (2019) pubmed
- WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy. (2022) pubmed
- Low MST1/2 and negative LATS1/2 expressions are associated with poor prognosis of colorectal cancers. (2023) pubmed
- MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. (2015) pubmed
- Phase separation of Hippo signalling complexes. (2023) pubmed
- Hippo signaling pathway and respiratory diseases. (2022) pubmed
- Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy. (2017) pubmed
- Hippo Signaling Pathway in Gliomas. (2021) pubmed
- HPV18 E7 inhibits LATS1 kinase and activates YAP1 by degrading PTPN14. (2024) pubmed
- Inhibiting Hippo pathway kinases releases WWC1 to promote AMPAR-dependent synaptic plasticity and long-term memory in mice. (2024) pubmed